ly3540378
Small moleculeexperimental
Clinical trial activity
3 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Mar 17, 2021 (NCT04768855)
Timeline
Indications
Mechanism of action
- Relaxin receptor 1AGONIST
RXFP1 agonist
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL6068449 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06598631 | Phase 2 | Oct 9, 2024 | Eli Lilly |
| NCT05592275 | Phase 2 | Nov 22, 2022 | Eli Lilly |
| NCT04768855 | Phase 1 | Mar 17, 2021 | Eli Lilly |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Eli Lilly | For profit | 3 | 3 | 2 | 2021 |
1 organizations
Page 1 / 1